True North Labs

Author: labstruenorth@gmail.com

  • FDA Vote Signals Growing Access to Peptide Therapies Through Telehealth

    The peptide therapy space is buzzing after a recent FDA advisory vote that industry watchers say could dramatically expand patient access to certain peptide compounds through telehealth channels. According to reporting from Fortune, the vote may set the stage for a multibillion-dollar market as more clinicians and patients gain streamlined access to these therapies.

    Peptides have gained significant attention in recent years for their potential roles in areas like metabolic health, recovery, and longevity-focused wellness protocols. Until now, regulatory uncertainty around certain peptide compounds has made it challenging for telehealth companies to scale their offerings. A favorable shift in FDA guidance could change that, giving legitimate telehealth providers clearer pathways to offer physician-supervised peptide protocols to a broader population.

    For patients, this kind of regulatory clarity is good news. Expanded telehealth access often means more convenient consultations, faster follow-up care, and the ability to work with knowledgeable providers regardless of geographic location. It also tends to encourage increased investment in quality control and manufacturing standards, as larger, well-capitalized telehealth companies enter the space and compete on both service and safety.

    Industry analysts quoted in the coverage suggest that this development could accelerate innovation in how peptide therapies are prescribed, monitored, and delivered to patients. A more defined regulatory framework can also encourage additional research and development, as companies gain more confidence to invest in clinical studies and formulation improvements when the regulatory path forward is clearer.

    As the peptide market matures, moves like this FDA vote could benefit patients by fostering more responsible, transparent, and accessible care models. True North Labs will continue to track how this regulatory shift unfolds and what it could mean for the future of peptide-based wellness protocols delivered through telehealth.

    This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider before starting any peptide therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: The FDA’s peptide vote could create telehealth’s next multibillion-dollar market – Fortune

  • FDA Advisory Panel Recommends Expanded Compounding Access for Six Peptides

    In a promising development for the peptide therapeutics community, a Food and Drug Administration advisory panel has recommended that six specific peptides be made available through compounding pharmacies. While final approval from the FDA is still pending, this recommendation signals a positive shift in how regulators are evaluating the therapeutic potential and safety profile of these compounds.

    Compounding pharmacies play a vital role in personalized medicine, allowing licensed pharmacists to prepare customized formulations of medications based on individual patient needs. When peptides are approved for compounding access, it often means patients and healthcare providers gain more flexibility in dosing, formulation, and administration methods that may not be available through standard commercial products.

    The panel’s endorsement suggests that these six peptides have demonstrated a favorable enough safety and efficacy profile to warrant expanded access through this specialized pharmaceutical channel. This kind of regulatory review process typically involves careful consideration of existing clinical data, manufacturing standards, and potential benefits to patient populations who may benefit from these therapies.

    For the broader peptide research and clinical community, this news represents encouraging momentum. Advisory panel recommendations, while not guarantees of final approval, often carry significant weight in shaping the FDA’s ultimate regulatory decisions. If finalized, this could open new pathways for patients to access these peptide-based treatments through trusted compounding pharmacy networks, potentially expanding treatment options in various therapeutic areas.

    The peptide field continues to evolve as regulatory bodies work to balance innovation with safety oversight. This panel recommendation reflects the ongoing dialogue between science, medicine, and policy that helps ensure promising compounds can eventually reach patients who might benefit from them, while maintaining appropriate quality and safety standards throughout the compounding process.

    This article is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider regarding any treatment decisions.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel backs compounding access for six peptides, approval still pending | Ukraine news – #Mezha – Межа. Новини України.

  • Ascletis Receives FDA Clearance to Begin Phase I Trial of Once-Monthly Obesity Peptide ASC35

    Ascletis Pharma has announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for ASC35, paving the way for a Phase I clinical trial in the United States. ASC35 is a dual agonist peptide designed to activate both the GLP-1 receptor and the GIP receptor, two pathways that have become central to modern approaches for weight management and metabolic health.

    What makes ASC35 particularly noteworthy is its once-monthly subcutaneous dosing schedule. Many currently available GLP-1-based therapies require weekly injections, so a treatment that could maintain efficacy with monthly administration may offer a meaningful convenience advantage for patients seeking long-term obesity management. Reduced dosing frequency has the potential to support easier treatment adherence, which is often a key factor in the long-term success of chronic disease management programs.

    The clearance of the IND application represents an important regulatory milestone, allowing Ascletis to move ASC35 from preclinical research into human testing. Phase I trials typically focus on evaluating safety, tolerability, and pharmacokinetics in a small group of participants, laying the groundwork for larger studies that would further assess effectiveness in the target patient population.

    The dual-agonist approach targeting both GLP-1 and GIP receptors builds on a growing body of scientific interest in incretin-based therapies for metabolic conditions. By engaging two complementary hormonal pathways, dual agonists like ASC35 aim to build on the therapeutic strategies already showing promise in the obesity treatment space, potentially broadening the range of options available to patients and physicians in the future.

    As this Phase I study gets underway, the peptide therapeutics field continues to see steady progress toward more convenient and effective options for individuals managing obesity. Continued clinical development will be needed to determine how ASC35 performs in terms of safety and effectiveness, but this regulatory clearance marks an encouraging step forward in that process. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity – PR Newswire

  • New Phase 1 Trial Launches to Study YL217 in Advanced Solid Tumors

    New Phase 1 Trial Launches to Study YL217 in Advanced Solid Tumors

    A new Phase 1 clinical trial has been registered to evaluate YL217, an investigational compound, in patients with advanced solid tumors. Listed on ClinicalTrials.gov, this first-in-human study represents an important early milestone in the development pipeline, as researchers begin to assess how the treatment behaves in the human body for the first time.

    First-in-human trials are a foundational step in bringing new therapies to patients. These early-phase studies are designed to evaluate safety, tolerability, and how a treatment is processed by the body, laying the groundwork for future studies that could eventually determine effectiveness against cancer. For patients with advanced solid tumors—who often face limited treatment options—every new investigational approach entering clinical testing offers a reason for cautious optimism.

    The oncology research field has seen a steady stream of innovative approaches in recent years, with peptide-based and targeted therapies increasingly playing a role in efforts to address hard-to-treat cancers. The initiation of this trial reflects the ongoing commitment within the research community to explore new mechanisms and expand the toolkit available to oncologists and patients alike.

    While it will take time before any conclusions can be drawn about YL217’s safety or potential benefits, the launch of this study is a positive sign of continued momentum in cancer research. Each new trial contributes valuable data to the broader scientific effort, and participants in these studies play a crucial role in advancing medical knowledge that could benefit future patients.

    True North Labs will continue to monitor this trial as it progresses and share updates as more information becomes available. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

  • New Clinical Trial Explores Efgartigimod as Potential Treatment for Guillain-Barré Syndrome

    New Clinical Trial Explores Efgartigimod as Potential Treatment for Guillain-Barré Syndrome

    Researchers have launched a new clinical trial called GREAT to evaluate efgartigimod as a potential treatment for Guillain-Barré syndrome (GBS), a rare autoimmune condition in which the body’s immune system mistakenly attacks the peripheral nervous system. This launch represents an encouraging step toward expanding the treatment options available to patients facing this challenging condition.

    Currently, standard treatment for GBS often relies on intravenous immunoglobulin (IVIg) or plasma exchange. The GREAT trial aims to determine whether efgartigimod, a therapy designed to target and reduce harmful antibodies, can offer similar or improved safety and effectiveness compared to existing options. By directly comparing efgartigimod against IVIg, researchers hope to gather clear data on how well the drug works and how safely it can be administered to GBS patients during hospitalization.

    The study design reflects a thoughtful, patient-centered approach. Participants will undergo six blood draws across follow-up visits to monitor levels of IgG antibodies, helping researchers understand how the treatment is affecting the immune response over time. Patients will also keep symptom and medication diaries, offering valuable real-world insight into how the treatment impacts daily life and recovery.

    This kind of rigorous, structured trial is an important part of how new therapies are responsibly brought forward for consideration. If efgartigimod proves to be both safe and effective for GBS, it could eventually provide clinicians and patients with another valuable tool in managing this autoimmune disorder, potentially complementing or even improving upon current treatment protocols. Expanding the range of available therapies is especially meaningful for conditions like GBS, where individual patient responses to treatment can vary significantly.

    While the trial is just getting underway and results will take time to materialize, its initiation is a hopeful sign of continued innovation in the treatment of rare autoimmune neurological conditions. The scientific community’s ongoing commitment to refining and diversifying therapeutic approaches offers real promise for patients and families affected by GBS.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)

  • New Study to Explore How Retained Natural Insulin Production Supports Diabetes Health

    A newly registered clinical trial is set to explore an encouraging area of diabetes research: how the body’s own residual insulin production, measured through a marker called C-peptide, might contribute to better quality of life and health outcomes for people living with insulin-treated diabetes. The study builds on years of prior research and aims to deepen scientific understanding of how preserving even small amounts of natural insulin function could be meaningfully beneficial.

    The research will draw on two large groups of participants. The first involves extending the existing StartRight study, which has already followed around 1,800 adults with new-onset diabetes for a median of four years. Participants with insulin-treated diabetes will be invited to take part in additional assessments, either remotely or in person, allowing researchers to track relationships between C-peptide levels and quality of life, mental health, and healthcare use over as long as nine years from diagnosis.

    The second part of the study will involve more than 2,500 participants with type 1 diabetes who have previously had C-peptide measured and agreed to be contacted for future research. From this group, roughly 200 individuals representing a range of C-peptide levels will be recruited for detailed testing. Researchers plan to compare different methods of measuring beta cell function—including practical, at-home approaches—to determine which best predicts glycaemic outcomes using continuous glucose monitoring data, as well as patient-reported wellbeing.

    What makes this research particularly promising is its focus on identifying practical, patient-friendly ways to measure a biological marker that may already be quietly supporting better health in many people with diabetes. If certain C-peptide measurement methods prove strongly linked to real-world benefits, it could pave the way for more personalized diabetes care in the future—potentially helping clinicians better tailor treatment plans based on each person’s remaining natural insulin production.

    By combining long-term observational data with detailed physiological testing, this study represents a thoughtful step toward better understanding the value of preserving endogenous insulin production, and could inform future strategies aimed at protecting or supporting this function in people living with diabetes. As with any ongoing research, results will take time to emerge, but the study’s scale and design offer a solid foundation for meaningful insights.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Benefits of Retained Insulin for Good Health

  • New Phase 2b Trial Launches to Explore Rezpegaldesleukin for Severe Alopecia Areata

    A new clinical trial, known as Rezolve AA, has begun enrolling adult participants to study rezpegaldesleukin (Rezpeg), an investigational pegylated recombinant human interleukin-2 peptide, as a potential treatment for severe to very severe alopecia areata. This Phase 2b study represents an encouraging step forward in the search for new therapeutic options for people living with this challenging autoimmune condition, which causes significant hair loss and can profoundly affect quality of life.

    The trial is designed as a randomized, double-blind, placebo-controlled study with three treatment arms, allowing researchers to carefully compare outcomes and gather reliable data on the peptide’s effects. Participants will undergo a 36-week treatment period, with an optional 16-week extension for those who wish to continue, followed by a 24-week follow-up period to monitor longer-term outcomes. This thorough, multi-phase design reflects a rigorous scientific approach aimed at generating meaningful insights into how rezpegaldesleukin may help modulate the immune response involved in alopecia areata.

    Interleukin-2-based therapies like rezpegaldesleukin are part of a growing area of peptide research focused on harnessing the body’s own regulatory immune pathways rather than broadly suppressing the immune system. This approach has generated interest across the scientific community as a potentially gentler and more targeted way to address autoimmune-driven conditions. If successful, this line of research could open new doors for patients who have limited options for managing severe hair loss caused by alopecia areata.

    The initiation of this Phase 2b trial highlights the continued momentum in peptide-based drug development and the dedication of researchers working to bring new, evidence-based treatments to those affected by autoimmune skin and hair conditions. As the study progresses through its screening, treatment, and follow-up phases, it will contribute valuable data to the broader understanding of interleukin-2 therapies and their role in immune regulation.

    True North Labs will continue to follow the progress of this trial with interest, as it represents another example of how peptide science is being applied to address unmet medical needs. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

  • TwoStep Therapeutics Secures $62.5M Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate

    TwoStep Therapeutics has announced two significant milestones in the same week: an oversubscribed $62.5 million Series A financing round and FDA clearance of its Investigational New Drug (IND) application for a first-in-class peptide-drug conjugate. The dual achievement signals strong investor confidence in the company’s approach and clears the path for the therapy to advance into human clinical trials.

    Peptide-drug conjugates represent an exciting frontier in targeted therapeutics, combining the precision-guiding properties of peptides with the therapeutic payload of a drug molecule. This approach is designed to deliver treatment more directly to target tissues, potentially improving efficacy while reducing off-target effects compared to more conventional drug delivery methods. TwoStep’s platform aims to bring this innovative strategy into practical clinical use, and the newly cleared IND will allow the company to begin testing this approach in patients.

    The oversubscribed nature of the Series A round is a notable vote of confidence from the investment community. When a funding round is oversubscribed, it typically means investor demand exceeded the company’s original fundraising target, reflecting enthusiasm about the science and the team behind it. This capital infusion will likely support the company’s efforts to move its lead peptide-drug conjugate through early-stage clinical development, build out its pipeline, and expand its research capabilities.

    For patients and the broader medical community, developments like this matter because they represent the kind of early-stage innovation that can eventually lead to new treatment options. While it’s still early days—an IND clearance means a company can begin clinical testing, not that a therapy has been proven safe or effective yet—each step through the regulatory and development pipeline brings promising new approaches closer to patients who may benefit from them.

    The peptide therapeutics field continues to attract substantial investment and regulatory attention, and news like TwoStep’s successful financing and IND clearance reflects the growing momentum behind peptide-based drug development more broadly. As the company moves toward clinical trials, the coming months and years will offer more insight into how this novel peptide-drug conjugate performs. This article is for informational purposes only and not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate – BioSpace

  • Teitur’s TT-P34 Peptide Shows Promising Early Results for Parkinson’s Disease

    Teitur’s TT-P34 Peptide Shows Promising Early Results for Parkinson’s Disease

    Teitur Trophics has announced positive early-stage findings for its investigational peptide TT-P34, developed as a potential treatment approach for Parkinson’s disease. The news offers a fresh dose of optimism in a field where new therapeutic options are urgently needed by patients and families navigating this challenging condition.

    Parkinson’s disease affects movement, coordination, and overall quality of life for millions of people worldwide, and current treatments primarily manage symptoms rather than addressing underlying disease mechanisms. Peptide-based approaches like TT-P34 represent a growing area of interest in neuroscience, as researchers explore how these smaller, targeted molecules might interact with specific biological pathways implicated in neurodegeneration.

    While details remain early-stage, the fact that Teitur is reporting favorable initial data is a meaningful milestone. Early positive signals in peptide development often pave the way for more extensive trials, helping companies refine dosing, understand safety profiles, and build the case for continued investment in a promising candidate. For the broader peptide research community, each successful early step reinforces confidence that peptide therapeutics can play a meaningful role in tackling complex neurological conditions.

    Parkinson’s research has seen a wave of innovative approaches in recent years, from gene therapies to novel small molecules, and peptides are increasingly recognized for their ability to precisely target biological processes with fewer off-target effects compared to some traditional drugs. TT-P34’s early progress adds to this momentum, suggesting that peptide science may offer new avenues worth exploring as researchers continue searching for treatments that could one day slow or modify disease progression rather than only easing symptoms.

    As with all early-stage findings, further research and larger trials will be needed to confirm these initial results and better understand TT-P34’s full potential. True North Labs will continue to follow Teitur’s progress with interest as this story develops. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Teitur reports positive early data for Parkinson’s peptide TT‑P34 – PharmaTimes

  • Peptide Therapy Shows Early Promise in Phase I Parkinson’s Trial

    Peptide Therapy Shows Early Promise in Phase I Parkinson’s Trial

    Encouraging news has emerged from the world of neurological research: a peptide-based therapy has reportedly performed well in a Phase I clinical trial targeting Parkinson’s disease, according to a report from BioXconomy. While full details of the trial design and results were not disclosed in initial coverage, the news signals a positive early milestone for peptide-based approaches to treating this challenging neurodegenerative condition.

    Phase I trials are typically the first stage at which an experimental therapy is tested in humans, with a primary focus on safety, tolerability, and how the body processes the treatment. A successful outcome at this stage is an important, though early, step—it suggests that researchers can move forward with more extensive studies to better understand the therapy’s potential benefits for people living with Parkinson’s disease.

    Peptides have become an increasingly promising area of biomedical research due to their ability to interact with the body’s cells and signaling pathways with high specificity. In the context of neurodegenerative diseases like Parkinson’s, researchers are exploring peptides that may help support neuronal health, reduce harmful protein aggregation, or otherwise influence the biological processes thought to contribute to disease progression.

    For the millions of people worldwide affected by Parkinson’s disease, any advancement that moves potential new treatments closer to reality is meaningful news. While it’s important to note that Phase I success does not guarantee that a therapy will ultimately prove effective in larger trials, it does represent a hopeful and necessary step in the long journey of drug development. Further studies—including Phase II and III trials—will be needed to establish efficacy and long-term safety in larger patient populations.

    True North Labs will continue to monitor developments in this promising area of peptide research and provide updates as more information becomes available. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Peptide therapy triumphs in Phase I Parkinson’s trials – BioXconomy